Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 10 April, 2014 and appeared in  Safety and Error PreventionMedicationIssue 724

Emergency Recall of the OTC Weight-loss Drug Alli

Several reports of tampering have been made nationwide.... 

Advertisement

Multiple reports of tampered Alli products have been reported throughout the United States, prompting an emergency recall of this OTC weight-loss drug.

Reports of tampered bottles containing different types of pills, in various shapes and colors, first began to pour in on Wednesday from consumers in Alabama, Florida, Louisiana, Mississippi, New York, North Carolina and Texas. Many of these bottles were missing labels, packed in a sealed box, and had tamper-evident seals that did not appear genuine.

The manufacturer, GlaxoSmithKline, is currently working with the U.S. Food and Drug Administration in their investigation. The stage in the supply chain where the productions were tampered with still remains unknown.

Product tampering is a serious crime in America and finding the source of this is essential. According to a spokeswoman for GlaxoSmithKline, "The investigation is ongoing... We've asked people to return bottles to us, so we can examine them very closely ... we don't have any theories at this point."

The contents found within the tampered Alli products are currently unknown. As of now, at least 20 inquiries have been made. No reports of harm have been reported.

Practice Pearls:
  • Alli is an OTC weight-loss supplement currently approved for obesity in adults in conjunction with a healthy diet
  • Weight-loss supplements are popular throughout the U.S. and many patients may be using them
  • Anyone who has purchased Alli® and believes it has been tampered with should contact the FDA and manufacture immediately

Hirschler B, Goodman D. GSK recalls weight-loss drug Alli in U.S. on tampering concerns. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 10 April, 2014 and appeared in  Safety and Error PreventionMedicationIssue 724

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014
Peripheral Neuropathy Associated with CV Disease and Stroke in Type 2 Diabetes Patients
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Molly Gee, MEd, RD

Category: Nutrition
Credits: .5



Search Articles On Diabetes In Control